Skopos Labs, Inc. Aldeyra Therapeutics, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 1,442 shares of ALDX stock, worth $7,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,442
Previous 1,442
-0.0%
Holding current value
$7,065
Previous $8,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALDX
# of Institutions
134Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$26.8 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$19.9 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$17.2 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT2.05MShares$10 Million1.29% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $286M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...